专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019094607A2 IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2019094607A2
公开(公告)日：2019-05-16
申请号：PCT/US2018/059849
申请日：2018-11-08
申请人： ADVAXIS, INC.
发明人： PETIT, Robert , PRINCIOTTA, Michael F. , CODER, Brandon , BALLI, David
摘要： Provided herein are tumor-associated antigen peptides comprising heteroclitic mutations and fusion polypeptides comprising such heteroclitic peptide. Also provided are nucleic acids encoding such peptides and fusion polypeptides, recombinant bacteria or Listeria strains comprising such peptides, fusion polypeptides, or nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such peptides, fusion polypeptides, nucleic acids, and recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such peptides, fusion polypeptides, nucleic acids, or recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such peptides, recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

2. 发明申请

WO2016154412A2 COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA BASED VACCINE FOR TREATING PANCREATIC CANCER 审中-公开
标题翻译： PD-1拮抗剂和基于LISTERIA的疫苗的组合用于治疗胰腺癌
公开(公告)号：WO2016154412A2
公开(公告)日：2016-09-29
申请号：PCT/US2016/023969
申请日：2016-03-24
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , ADVAXIS, INC.
发明人： BEATTY, Gregory L. , KNOBLOCK, Dawson , PETIT, Robert , PRINCIOTTA, Michael F. , WALLECHA, Anu
IPC分类号： A61K39/12 , A61K39/395 , A61K48/00 , A61P35/00
CPC分类号： A61K39/12 , A61K39/00 , A61K39/395 , A61K48/00 , A61K2039/55544 , A61K2039/585
摘要： The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the treatment of pancreatic cancer using an antagonist of a Programmed Death 1 protein (PD-1) in combination with a live attenuated recombinant Listeria strain comprising a fusion protein of a PEST sequence-containing polypeptide fused to a tumor-associated antigen.
摘要翻译：本发明涉及可用于治疗癌症的组合疗法。特别地，本发明涉及使用程序性死亡1蛋白（PD-1）的拮抗剂与活的减毒重组利斯特氏菌菌株联合治疗胰腺癌，其包含与肿瘤融合的含有PEST序列的多肽的融合蛋白相关抗原。

3. 发明申请

WO2016126876A2 LISTERIA-BASED ADJUVANTS 审中-公开
标题翻译：基于LISTERIA的ADJUVANTS
公开(公告)号：WO2016126876A2
公开(公告)日：2016-08-11
申请号：PCT/US2016/016452
申请日：2016-02-03
申请人： ADVAXIS, INC.
发明人： PETIT, Robert
IPC分类号： A61K39/39 , A61K39/02 , A61K35/74 , A61K48/00 , C12N15/74 , C12N9/10 , C12N9/16 , C12N9/88 , C07K14/195
CPC分类号： A61K35/74 , A61K39/001 , A61K39/0208 , A61K39/39 , A61K2039/522 , A61K2039/577 , A61K2039/585 , C07K14/195 , C07K14/335
摘要： This disclosure provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject. In certain instances, methods of this disclosure may be useful for subjects receiving a transplant.
摘要翻译：本公开提供了使用单核细胞增多性李斯特菌素作为佐剂以增强受试者的免疫应答的方法和组合物。在某些情况下，本公开的方法可用于接受移植的受试者。

4. 发明申请

WO2019094607A3 IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2019094607A3
公开(公告)日：2019-05-16
申请号：PCT/US2018/059849
申请日：2018-11-08
申请人： ADVAXIS, INC.
发明人： PETIT, Robert , PRINCIOTTA, Michael, F. , CODER, Brandon , BALLI, David
IPC分类号： C07K7/06 , C12N15/74 , A61K39/00 , A61K39/39 , A61P35/00
摘要： Provided herein are tumor-associated antigen peptides comprising heteroclitic mutations and fusion polypeptides comprising such heteroclitic peptide. Also provided are nucleic acids encoding such peptides and fusion polypeptides, recombinant bacteria or Listeria strains comprising such peptides, fusion polypeptides, or nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such peptides, fusion polypeptides, nucleic acids, and recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such peptides, fusion polypeptides, nucleic acids, or recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such peptides, recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

5. 发明申请

WO2018129306A1 RECOMBINANT LISTERIA VACCINE STRAINS AND METHODS OF USING THE SAME IN CANCER IMMUNOTHERAPY 审中-公开
公开(公告)号：WO2018129306A1
公开(公告)日：2018-07-12
申请号：PCT/US2018/012570
申请日：2018-01-05
申请人： ADVAXIS, INC.
发明人： PETIT, Robert
IPC分类号： C12N15/74 , C07K14/005 , C07K14/195 , A61K39/02 , A61K39/00 , A61P35/00
CPC分类号： A61P35/00 , A61K39/00 , A61K39/02 , A61K39/12 , A61K2039/522 , A61K2039/523 , A61K2039/585 , A61K2039/6068 , A61K2039/86 , C07K14/195 , C12N2710/20034
摘要： Provided herein are recombinant fusion polypeptides comprising an HPV16 antigenic peptide and an HPV18 antigenic peptide, wherein the HPV16 antigenic peptide and the HPV18 antigenic peptide are operably linked in tandem (e.g., fused to a PEST- containing peptide). Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

6. 发明申请

WO2017132547A1 PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF 审中-公开
标题翻译：个性化递送基于传播的免疫疗法及其应用
公开(公告)号：WO2017132547A1
公开(公告)日：2017-08-03
申请号：PCT/US2017/015403
申请日：2017-01-27
申请人： ADVAXIS, INC.
发明人： PETIT, Robert , PERRY, Kyle , PRINCIOTTA, Michael F.
IPC分类号： C12N15/74 , C12N15/66 , C07K5/10 , C07K14/705 , A61K35/74 , A61K39/00 , A61K48/00
CPC分类号： A61K35/74 , A01K2267/0331 , A61K38/1709 , A61K39/0011 , A61K47/64 , A61K47/646 , A61K2039/522 , A61K2039/523 , A61K2039/6068 , C07K5/10 , C07K14/47 , C07K14/705 , C07K19/00
摘要： Disclosed herein is a personalized immunotherapy composition for a subject having a disease or condition, including therapeutic vaccine delivery vectors and methods of making the same comprising gene expression constructs expressing frameshift-mutation-derived peptides associated with one or more neo-epitopes encoded by nucleic acid sequences comprising at least one frameshift mutation, wherein the frameshift mutation is specific to a subject's cancer or unhealthy tissue. A delivery vector of this disclosure includes bacterial vectors; or viral vectors, or peptide vaccine vectors; or DNA vaccine vectors including Listeria bacterial vectors comprising one or more fusion proteins comprising one or more frameshift-mutation-derived peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. Disclosed are also methods of using these compositions for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection in the subject.
摘要翻译：本文公开了用于患有疾病或病症的受试者的个体化免疫治疗组合物，包括治疗性疫苗递送载体及其制备方法，所述方法包括表达移码突变衍生肽与基因表达构建体相关的基因表达构建体，由包含至少一个移码突变的核酸序列编码的更多新表位，其中移码突变对个体的癌症或不健康组织特异。本公开的递送载体包括细菌载体; 或病毒载体或肽疫苗载体; 或DNA疫苗载体，包括含有一种或多种融合蛋白的李斯特菌细菌载体，所述融合蛋白包含一种或多种移码突变衍生的肽，所述肽包含存在于患有受试者的疾病的生物样品中存在的一种或多种新表位。还公开了使用这些组合物诱导抗疾病或病症（包括肿瘤或癌症）或受试者感染的免疫应答的方法。

7. 发明申请

WO2016011353A1 RECOMBINANT LISTERIA STRAIN EXPRESSING HETEROLOGOUS ANTIGEN FUSION PROTEINS AND METHODS OF USE THEREOF 审中-公开
标题翻译：表达异源抗原融合蛋白的重组LISTERIA菌株及其使用方法
公开(公告)号：WO2016011353A1
公开(公告)日：2016-01-21
申请号：PCT/US2015/040911
申请日：2015-07-17
申请人： ADVAXIS, INC.
发明人： WALLECHA, Anu , PETIT, Robert , ELLENHORN, Joshua , DIAMOND, Don J.
IPC分类号： A61K39/02 , A61K35/74 , A61K39/12 , A61P35/00
CPC分类号： A61K39/0011 , A61K35/74 , A61K39/385 , A61K2039/522 , A61K2039/523 , A61K2039/572 , A61K2039/6037 , A61P35/00 , C07K14/195 , C07K14/4703 , C07K2319/40 , C07K2319/55 , C12N9/90 , C12N15/85 , C12N2800/107 , C12N2820/55 , C12Y501/01001
摘要： Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant Listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
摘要翻译：本文公开了编码与免疫原性多肽融合的肿瘤抗原的重组核酸和包含其的重组利斯特氏菌菌株，其制备方法，以及诱导免疫应答的方法，以及治疗，抑制或抑制癌症或肿瘤的方法，包括对其施用。

8. 发明公开

EP3481854A1 LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：EP3481854A1
公开(公告)日：2019-05-15
申请号：EP17824750.8
申请日：2017-06-30
申请人： Advaxis, Inc.
发明人： PRINCIOTTA, Michael , PETIT, Robert
IPC分类号： C07K14/47 , C12N15/74 , A61K39/00 , A61K48/00

9. 发明公开

EP3234148A1 COMBINATION THERAPIES WITH RECOMBINANT LISTERIA STRAINS 审中-公开
标题翻译：联合治疗与重组李斯特菌菌株
公开(公告)号：EP3234148A1
公开(公告)日：2017-10-25
申请号：EP15871237.2
申请日：2015-12-18
申请人： The Trustees of The University of Pennsylvania , Advaxis, Inc.
发明人： PETIT, Robert , WALLECHA, Anu , PATERSON, Yvonne , SINGH, Reshma
IPC分类号： C12N15/70 , C12N15/62 , C07K14/195 , C07K14/47 , C07K14/025 , C07K14/705 , C07K16/28 , A61K39/00 , A61K39/02 , A61K39/39
CPC分类号： A61K39/0011 , A61K2039/505 , A61K2039/522 , A61K2039/572 , C07K14/025 , C07K14/195 , C07K16/2818 , C07K2319/40 , C07K2319/95
摘要： Disclosed herein are compositions comprising use of compositions comprising a live attenuated recombinant Listeria strain comprising a fusion protein of a truncated listeriolysin O (LLO) protein, a truncated ActA protein, or a PEST amino acid sequence fused to a heterologous antigen, including a tumor-associated antigen, wherein the compositions further comprise or are co-administered with an antibody or fragment thereof. Also disclosed are combination therapies comprising use of these compositions comprising live attenuated recombinant Listeria strains, in conjunction with an antibody or fragment thereof for use in treating, protecting against, and/or inducing an immune response against a tumor, especially wherein the treating, protection against and/or inducing an immune response increases percent survival in a subject.
摘要翻译：本公开内容涉及包含溶瘤病毒，嵌合抗原受体T细胞（CAR T细胞），治疗性或免疫调节性单克隆抗体，靶向胸苷激酶抑制剂（TKI）或掺入工程化T细胞受体的过继转移细胞的组合物，以及包含与肿瘤相关抗原融合的截短的LLO，截短的ActA或PEST序列肽的融合蛋白的活减毒重组利斯特氏菌菌株。本公开还涉及治疗，防止和诱导针对肿瘤的免疫应答的方法，包括在有或没有另外的放射疗法治疗的情况下施用所述免疫应答的步骤。

10. 发明申请

WO2019006401A2 LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETEROCLITIC WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2019006401A2
公开(公告)日：2019-01-03
申请号：PCT/US2018/040457
申请日：2018-06-29
申请人： ADVAXIS, INC. , SELLAS LIFE SCIENCES GROUP LTD.
发明人： PRINCIOTTA, Michael , PETIT, Robert , GUTIERREZ, Andres A.
IPC分类号： C12N15/74 , C07K14/47 , C07K14/195 , A61K39/00 , A61K39/39 , A61P35/00
CPC分类号： A61P35/00 , A61K39/00 , A61K39/001153 , A61K39/02 , A61K39/39 , A61K2039/55516 , C07K14/4748 , C07K2319/00 , C07K2319/40 , C07K2319/95 , C12N15/62
摘要： Provided herein are recombinant fusion polypeptides comprising one or more antigenic Wilms tumor protein (WT1) peptides, wherein at least one of the antigenic WT1 peptides is a heteroclitic mutant WT1 peptide (e.g., fused to a PEST-containing peptide). Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-WT1 immune response in a subject, methods of inducing an anti-WT1-expressing-tumor or anti-WT1-expressing-cancer immune response in a subject, methods of treating a WT1-expressing or WT1-associated tumor or cancer in a subject, methods of preventing a WT1-expressing or WT1-associated tumor or cancer in a subject, and methods of protecting a subject against a WT1-expressing or WT1-associated tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式